Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia
About this trial
This is an interventional supportive care trial for Acute Lymphoblastic Leukemia
Eligibility Criteria
Inclusion Criteria: Age >= 60 years Diagnosed with hematologic malignancy or bone marrow failure syndrome eligible for allogeneic hematopoietic cell transplantation. This includes acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, myelofibrosis, chronic myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma, and aplastic anemia. Disease specific eligibility for allo-HCT to be determined by treating physician Must be able to understand written and spoken English Must be willing to attend all study visits and comply with study procedures for the entire length of the study Exclusion Criteria: Documented history of dementia No possibility of proceeding to allogeneic hematopoietic cell transplant within the next 6 months as determined by treating physician Scheduled admission for allogeneic hematopoietic cell transplant within 30 days of enrollment Inability or unwillingness to give written informed consent
Sites / Locations
- Ohio State University Comprehensive Cancer Center
Arms of the Study
Arm 1
Experimental
Supportive care (GO!)
Patients undergo personalized GO! plan consisting of study visits over 50 minutes at baseline and 6 months after first visit or at the time of hospital admission for bone marrow transplant and over 25 minutes at 3 and 12 months after transplant. Patients complete questionnaires once a month for up to 6 months and wear an accelerometer for up to 6 months.